{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:43:21Z","timestamp":1786740201166,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006940","name":"The University of Mississippi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006940","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.anai.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:45:29Z","timestamp":1783529129000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New pharmaceutical options for patients with allergic and asthma-related diseases"],"prefix":"10.1016","author":[{"given":"Charles E.","family":"Grogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4092-6556","authenticated-orcid":false,"suffix":"Jr","given":"Gailen D.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.anai.2026.07.004_bib0001","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.iac.2004.06.002","article-title":"Anti-IgE therapy","volume":"24","author":"Brownell","year":"2004","journal-title":"Immunol Allergy Clin North Am."},{"key":"10.1016\/j.anai.2026.07.004_bib0002","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.immunol.21.120601.141103","article-title":"The biology of IGE and the basis of allergic disease","volume":"21","author":"Gould","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.anai.2026.07.004_bib0003","unstructured":"Genentech. Xolair (omalizumab) prescribing information. Accessed February 2026. Available at: https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf"},{"issue":"6","key":"10.1016\/j.anai.2026.07.004_bib0004","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.07.004_bib0005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.11.005","article-title":"Omalizumab safety concerns","volume":"155","author":"Pongdee","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.07.004_bib0007","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.jaci.2016.12.953","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo controlled clinical trials","volume":"139","author":"Iribarren","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2026.07.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100695","article-title":"Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma","volume":"15","author":"Hanania","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"2","key":"10.1016\/j.anai.2026.07.004_bib0009","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","article-title":"Safety of antiimmunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection","volume":"37","author":"Cruz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2026.07.004_bib0010","unstructured":"GlaxoSmithKline. Nucala (mepolizumab) prescribing information. Accessed February 2026. Available at: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF"},{"key":"10.1016\/j.anai.2026.07.004_bib0011","unstructured":"Teva Respiratory. Cinqair (reslizumab) prescribing information. Accessed February 2026. Available at: https:\/\/www.cinqair.com\/globalassets\/cinqair\/prescribinginformation.pdf"},{"key":"10.1016\/j.anai.2026.07.004_bib0012","unstructured":"AstraZeneca. Fasenra (Benralizumab) prescribing information. Accessed February 2026. Available at: https:\/\/drd9vrdh9yh09.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/3647bed4-ce91-4fe7-9bc5-32dbee73f80a\/3647bed4-ce91-4fe7-9bc5-32dbee73f80a_viewable_rendition__v.pdf"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0013","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2417184","article-title":"Long-term safety of mepolizumab for up to \u223c10 years in patients with severe asthma: open-label extension study","volume":"56","author":"Pavord","year":"2024","journal-title":"Ann Med"},{"issue":"5","key":"10.1016\/j.anai.2026.07.004_bib0014","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.07.004_bib0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaip.2019.07.038","article-title":"Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials","volume":"8","author":"Virchow","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.anai.2026.07.004_bib0016","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving Benralizumab for Up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2026.07.004_bib0017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-2776(08)01003-1","article-title":"Biology of the eosinophil","volume":"101","author":"Blanchard","year":"2009","journal-title":"Adv Immunol."},{"key":"10.1016\/j.anai.2026.07.004_bib0018","unstructured":"Regeneron Pharmaceuticals. Dupixent (Dupilumab) prescribing information. Accessed February 2026. Available at: https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf"},{"issue":"3","key":"10.1016\/j.anai.2026.07.004_bib0019","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2026.07.004_bib0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.07.004_bib0021","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ced\/llad390","article-title":"Dupilumab-associated inflammatory arthritis: a literature review","volume":"49","author":"Napolitano","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2026.07.004_bib0022","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.20138","article-title":"Dupilumab-associated arthralgia: an observational retrospective study in VigiBase\u00ae","volume":"185","author":"Chr\u00e9tien","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2026.07.004_bib0023","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.07.004_bib0024","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.anai.2024.05.014","volume":"133","author":"Lieberman","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2026.07.004_bib0025","unstructured":"Leo Pharma, ADBRY (tralokinumab-ldrm) prescribing information. Accessed February 2026. Available at: https:\/\/mc-df05ef79-e68e-4c65-8ea2-953494-cdn-endpoint.azureedge.net\/-\/media\/corporatecommunications\/us\/therapeutic-expertise\/our-product\/adbrypi.pdf?rev=a2b53c02115e4d898c1589b28d8c05b6#page=19"},{"key":"10.1016\/j.anai.2026.07.004_bib0026","unstructured":"Eli Lilly and Company. Ebglyss (lebrikizumab-lbkz) prescribing information. Accessed February 2026. Available at: https:\/\/uspl.lilly.com\/ebglyss\/ebglyss.html#pi"},{"issue":"3","key":"10.1016\/j.anai.2026.07.004_bib0027","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2026.07.004_bib0028","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s13555-026-01656-7","article-title":"Long-term safety and efficacy of tralokinumab in patients with moderate-to-severe atopic dermatitis treated for up to 6 years: final results from the open-label extension trial ECZTEND","volume":"16","author":"Blauvelt","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"10.1016\/j.anai.2026.07.004_bib0029","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","article-title":"Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials","volume":"24","author":"Stein Gold","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.anai.2026.07.004_bib0030","unstructured":"AstraZeneca. Tezspire (Tezepelumab) prescribing information. Accessed February 2026. Available at: https:\/\/drd9vrdh9yh09.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/e306dc06-d580-4457-b15f-9f28545ad63a\/e306dc06-d580-4457-b15f-9f28545ad63a_viewable_rendition__v.pdf"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0031","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/02770903.2024.2385973","article-title":"Long-term safety of tezepelumab in patients with asthma: a systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Qin","year":"2025","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0032","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Ebina-Shibuya","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.anai.2026.07.004_bib0033","unstructured":"Galderma Laboratories. Nemluvio (nemolizumab-ilto) prescribing information. Accessed February 2026. Available at: https:\/\/www.galderma.com\/sites\/default\/files\/2024-12\/Nemluvio_Dual%20PI%20for%20website%2013Dec24.pdf"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/bjd\/ljaf045","article-title":"Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged \u2265 13 years: efficacy and safety data from a phase II\/III study","volume":"193","author":"Yokozeki","year":"2025","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.07.004_bib0035","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/bjd\/ljae458","article-title":"Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study","volume":"192","author":"Igarashi","year":"2025","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2026.07.004_bib0036","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.anai.2025.11.007","article-title":"Interleukin-31 targeting and other novel drugs in itch","volume":"136","author":"Olah","year":"2026","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2026.07.004_bib0037","article-title":"GINA report for asthma [e-pub ahead of print]","author":"Venkatesan","year":"2025","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.anai.2026.07.004_bib0038","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/JAA.S507008","article-title":"Combining dual biologics therapy for severe asthma: A series of ten cases","volume":"18","author":"Chen","year":"2025","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0039","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaip.2022.09.036","article-title":"A case series of dual biologics therapy for severe asthma","volume":"11","author":"Serajeddini","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2026.07.004_bib0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/02770903.2023.2260884","article-title":"Dual biologics therapy in a patient with severe asthma and chronic urticaria: a case report and review of the literature","volume":"61","author":"Can Bostan","year":"2024","journal-title":"J Asthma"},{"issue":"11","key":"10.1016\/j.anai.2026.07.004_bib0041","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/jpm13111594","article-title":"Combination of biological therapy in severe asthma: where we are?","volume":"13","author":"Carriera","year":"2023","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.anai.2026.07.004_bib0042","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anai.2019.06.013","article-title":"Combination biologic therapy for severe persistent asthma","volume":"123","author":"Ortega","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.07.004_bib0043","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0044","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","article-title":"Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis","volume":"160","author":"Ingrassia","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2026.07.004_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.anai.2026.07.004_bib0046","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","article-title":"Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: a population-based cohort study","volume":"154","author":"Tsai","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.07.004_bib0047","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/pharmaceutics15020385","article-title":"Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis","volume":"15","author":"Iznardo","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0048","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.anai.2026.07.004_bib0049","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor\u2013dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.anai.2026.07.004_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"10.1016\/j.anai.2026.07.004_bib0051","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0052","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/cts.13126","article-title":"Novel bruton's tyrosine kinase inhibitor remibrutinib: drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling","volume":"15","author":"Huth","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.anai.2026.07.004_bib0053","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","article-title":"Update on Roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease","volume":"163","author":"Rabe","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"9454","key":"10.1016\/j.anai.2026.07.004_bib0054","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(05)17708-3","article-title":"Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease","volume":"365","author":"Lipworth","year":"2005","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.anai.2026.07.004_bib0055","first-page":"S28","article-title":"Supplement Issue: Roflumilast for asthma","volume":"35","author":"Cazzola","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.anai.2026.07.004_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.anai.2026.07.004_bib0057","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-022-01714-5","article-title":"Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma","volume":"28","author":"Kachroo","year":"2022","journal-title":"Nat Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:53:44Z","timestamp":1786737224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626003352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"alternative-id":["S1081120626003352"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.004","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New pharmaceutical options for patients with allergic and asthma-related diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}